Objective: To evaluate the safety and efficacy of GlucoStabilizer software intravenous insulin (IV) dosing in comparison to American Diabetes Association (ADA) protocol-directed provider-guided insulin dose adjustment (PGIA).
INTRODUCTION
The pursuit of safer and more effective management of diabetic ketoacidosis (DKA) stems from it being one of the most serious metabolic complications of diabetes that requires intensive monitoring. Maghrabi et al. (1) demonstrated that standardization of DKA management yields superior outcomes. They performed a retrospective chart review of patients with DKA managed before and after implementation of an algorithm-based protocol. Utilization of an algorithm-based protocol resulted in reduced time to resolution of DKA and fewer hypoglycemic episodes without compromising electrolyte imbalance. Another study demonstrated that the use of a standardized protocol for management of DKA reduced the frequency of inappropriate discontinuation of intravenous insulin and recurrence of DKA (2) .
The American Diabetes Association (ADA) consensus statement provides algorithm-based recommendations for the treatment of DKA including intravenous (IV) insulin dosing (3) . The IV insulin dosing protocol includes a weight-based starting dose followed by dosing guidelines linked with the rate of glucose decline.
A review article analyzed a total of 85 articles published between 1973 and 2016 and found that "intravenous insulin rates remain contentious" and cite a lack of studies guiding insulin dosing (4) . In effort to manage DKA, many institutions have relied on either the ADA dosing guidelines or standardized paper-based algorithms to dose intravenous insulin infusion rates. Paper-based insulin-dosing algorithms do not usually take into account patient-specific blood glucose trends and result in oscillation between hypoglycemia and hyperglycemia (5) . In addition, the commonly used (original and updated IIP) Yale insulin infusion protocol clearly states that it should not be used in the treatment of DKA (6) .
Currently, four electronic glycemic management systems (eGMS) are commercially available for intravenous insulin infusion dosing (7) . Glucommander ™(Glytec® Systems, Waltham, Software-guided insulin dosing calculators have been studied widely demonstrating substantial evidence that that they can be safely and effectively used to treat hyperglycemia in both ICUs and general medical or surgical units. Moreover, numerous studies have demonstrated superiority and/or non-inferiority of software-guided insulin dosing calculators as compared to use of manual protocols or provider guided dosing in attaining prescribed target glucose levels and avoiding hyper/hypoglycemia and electrolyte derangements (5, (8) (9) (10) (11) (12) . These eGMS systems do not use the same algorithms and to date, there have been no head-to-head studies comparing the systems. GlucoStabilizer and other insulin infusion dosing software programs were designed to maintain blood glucose in a target range for effective treatment of hyperglycemia but have been sparsely tested for management of DKA in adults (9, 13, 14) .
GlucoStabilizer Settings for the Treatment of DKA
GlucoStabilizer is a software-guided insulin dosing system that calculates the required dose of IV insulin based on target glucose range and adjusts rates based on an individual's response to treatment with the use of an insulin sensitivity factor (ISF) called a multiplier. The multiplier is an key component of the insulin dose calculation as it models the patients glycemic response to insulin (11) . For example, a multiplier of 0.03 increases the insulin dose by 0.03 units/hour for each mg/dL increase in the blood glucose. When the next blood glucose value is entered, the software calculates the next multiplier and infusion rate. eGMS programs such as GlucoStabilizer are capable of reliably calculating insulin doses to maintain blood glucose in target range and alert nurses when to measure patients' blood glucose thereby reducing hypoglycemia and errors (7, 9, 10, 13) .
Utilization of software programs for insulin dosing in the treatment of DKA has limitations that must be appreciated. Residents who are largely responsible for dosing insulin in academic institutions can misconstrue the difference in the primary role of insulin for treating hyperglycemia as compared to the role of insulin in the management of DKA. In treating hyperglycemia, the role of an intravenous insulin infusion is to reduce blood glucose levels to a designated target range.
However, when managing DKA, the primary role of the continuous intravenous insulin infusion is to resolve acidosis, with improvement in glucose values as a secondary benefit. A more gradual decline in blood glucose is desired to prevent episodes of hypoglycemia while attaining resolution of ketoacidosis (15) . Thus, the rates of insulin infusion based on tested insulin sensitivity factors and target blood glucose ranges used in managing hyperglycemia will not apply when managing patients with DKA.
Traditionally, studies have used time to resolution of DKA as a surrogate endpoint for patient outcomes. However, thus far, no studies have demonstrated that faster correction of DKA leads to better outcomes. In fact, the opposite is likely true. Lower rates of insulin infusion result in more gradual reduction in plasma osmolality, fewer complications including episodes of hypoglycemia, hypokalemia, cerebral edema, and no difference of time spent in the ICU (4, 15) . Rapid resolution of DKA is an endpoint that does not necessarily correlate with better clinical outcomes.
When NYU Winthrop began using GlucoStabilizer for IV insulin dosing in the treatment of DKA, there were no published studies recommending insulin sensitivity factors or glucose target ranges. The team chose an initial multiplier of 0.01 and target range of 140-200 mg/dL to allow for a more steady decline in blood glucose and minimize hypoglycemia. There was no IV insulin bolus given prior to initiation of GlucoStabilizer. It is important to note that insulin infusion software is focused solely on glucose values and maintaining them in target range. Thus, potentially if glycemic target range is attained but the patient is still in acidosis, the software may recommend reducing the infusion rate to 0 units/hr. Doing so prior to resolution of acidosis in DKA would prolong treatment. Instead, the staff is educated and instructed to override the GlucoStabilizer-guided dose DOI:10.4158/EP-2019-0510 © 2020 AACE. of zero to continue IV insulin infusing at the rate of 0.3 units/hr and increase the rate of dextrose infusion to support continued IV insulin infusion.
The staff of NYU Winthrop successfully utilizes GlucoStabilizer to manage hyperglycemia for patients admitted to the ICU, post cardiac surgery, antepartum and intrapartum (16) . Our aims were: to modify the settings of GlucoStabilizer and apply them to successfully manage DKA in the ICU; and to evaluate the safety and efficacy of GlucoStabilizer software dosing in comparison to ADA protocol-directed provider-guided insulin dose adjustment.
METHODS
This study used a quasi-experimental design involving before and after period (17) . The Hypoglycemia was defined as blood glucose <70mg/dL, clinically significant hypoglycemia was defined as blood glucose < 54 mg/dL (18) and severe hypoglycemia was defined as blood glucose <40mg/dL. Metabolic profile was measured routinely, every 4-6 hours and hypokalemia was defined as potassium levels <3.3 mEq/L. The evaluation of the efficacy and safety of GlucoStabilizer Patients with end-stage renal disease, those diagnosed with hyperosmolar hyperglycemic state (defined as plasma glucose >600mg/dL; arterial pH>7.3; serum bicarbonate >18mEq/L; effective serum osmolality >320mOsm/Kg) and those with sodium-glucose co-transporter 2 (SGLT2) inhibitor-associated euglycemic DKA were excluded from the study. Patients managed by both methods of insulin infusion during same hospital stay were also excluded.
Statistical Methods
Data were summarized using descriptive statistics such as mean (SD), median (Q1-Q3) For the final model reported, an exhaustive search of the model space was conducted and models were ranked on the basis of their adjusted R 2 values. All analyses were conducted using SAS 9.4 (SAS Institute Inc, Cary, NC) and results were considered significant if p<0.05.
RESULTS

In this study of a total of 146 patients, 77 had IV insulin infusion doses calculated by
GlucoStabilizer software and 69 had ADA protocol-directed PGIA. The demographics and clinical characteristics of the study patients are shown in Table 1 . There were no differences in the mean DOI:10.4158/EP-2019-0510 © 2020 AACE. age, BMI, weight, gender, HbA1c, pH in ED, or bicarbonate level between the intervention and comparison groups.
In the intervention group, the mean time to DKA resolution 9.8 (6.8-17. 3) hours and time to blood glucose target 6.7 (4.1-9.8) hours were not statistically different than the comparison group 9.9 (6.1-15.8) hours and 4.6 (3.1-10.30) hours, respectively. There was no difference in number of episodes of hypokalemia between groups 9 (11.7%) vs 11 (15.9%) p=0.48. (Table 2 ).
Ten patients in the ADA protocol-directed PGIA group had at least one episode of hypoglycemia (14.5%) defined as blood glucose < 70 mg/dL compared to no hypoglycemia in the 
DISCUSSION
This study has demonstrated that management of IV insulin dosing in adult patients with DKA using GlucoStabilizer software is superior to that of ADA protocol-directed PGIA in preventing hypoglycemia. It is non-inferior in meeting time to reaching glycemic target, time to DKA resolution, and preventing hypokalemia. There was no negative impact on safety in our patient population.
Hypoglycemia is a major parameter in evaluating the safety of an IV insulin dosing method in the treatment of DKA. It remains a significant concern in hospitalized patients as it may be an independent risk factor for increased mortality and poor clinical outcomes. Hypoglycemia can cause brain metabolic dysfunction due to impaired glucose metabolism and increase the risk of ventricular arrhythmias due to QT interval prolongation (8) . Other feared consequences of hypoglycemia include seizures and hypoglycemic coma (19) . For these reasons, management of DKA requires an insulin dosing approach that reduces the risk of hypoglycemia and its complications, a goal that GlucoStabilizer software has successfully accomplished in this study (N=0 patients with hypoglycemia compared to N=10 on ADA protocol-directed PGIA).
This study targeted rate of hypokalemia as a measure of safe DKA management since disturbance in serum potassium concentration can have fatal arrhythmogenic potentials.
Hypokalemia is one of the most commonly encountered electrolyte abnormalities in medicine and with a higher risk during insulin infusion as insulin causes a flux of potassium into cells. There was no difference in the rate of hypokalemia between the intervention and comparison group (p=0.48).
Since medical residents were largely responsible for measuring and repleting electrolytes, the use of GlucoStabilizer vs. ADA protocol-directed PGIA may not have been a significant factor in regulating serum potassium concentrations. A higher powered research study would be needed to evaluate if this was a type II error of our study.
When DKA was managed viaADA protocol-directed provider-guided insulin dosing, there was a delay in timely insulin dose adjustment because medical residents were interrupted in their care of other patients when called with the hourly blood glucose results. This lag in time could have contributed to episodes of hypoglycemia electrolyte derangements and amount of insulin prescribed. Management of DKA with GlucoStabilizer, however, allows for adjustment of insulin rates immediately as needed without the need for hourly input from medical residents. In addition, software-generated reminders for nurses to check blood glucose every 60 minutes along with data fields and reports that emphasize overdue glucose checks contribute to timely dose adjustment with eGMS. Similarly, the broad dosing guidelines in the ADA protocol are not as sensitive as the eGMS software-determined doses which may have contributed to the greater number of insulin units presecribed in the PGIA group.
Three published reports have focused on managing DKA in adults with the use of softwareguided insulin infusion. The first retrospective chart review focused on the use of Glucommander to manage DKA in the emergency department (ED) and demonstrated its utility in distinguishing those patients who need admission to inpatient care versus those who can be discharged from the ED (13) . Of the 35 patients included, 16 patients were discharged from the ED directly and 19 were admitted. The authors report 18 episodes of hypoglycemia (<70 mg/dL) with no episodes less than 40 mg/dL. The authors describe the glucose target range and multiplier as physician selected but these settings were not included in the paper.
A retrospective multicenter study involving 1750 patients treated with eGMS compared the use of Glucommander versus column-based protocols such as the Yale or Leuven protocols in adult patients admitted to the ICU or step-down floors to dose IV insulin infusions in the management of DKA (9) . The study included various glucose target ranges in Glucommander chosen by individual sites (100-140 mg/dL; 120-160 mg/dL; 140-180 mg/dL; 160-180 mg/dL) and 
